Compass Pathways President Steps Down To An Advisory Role

Compass Pathways (Nasdaq: CMPS) announced this morning major changes to its executive team. One of its co-founders, President and Chief Business Officer Lars Wilde is stepping down to take a senior advisory role.

“We have built an amazing company at COMPASS and I am grateful to everyone who continues to support us,” Wilde said in a statement. “This is a natural time for me to transition to an advisory role and I am proud to be able to continue working with COMPASS.”

The move is effective as of January 1, 2022.

Wilde is said to have been integral to the company’s strategic and operational efforts, “including fundraising, business development, and the development of its Discovery Center.”

The firm also announced Matthew Owens as its General Counsel and Chief Legal Officer starting February 1, 2022, while Mike Falvey was announced as the incoming CFO earlier this month.

Compass Pathways last traded at US$23.73 on the Nasdaq.


Information for this briefing was found via Edgar and Compass Pathways. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Russell Will Lead the Next Market Crash!? | John Feneck

The Global Conflict Has Already Started | Bryan Cunningham

Silver Still At 90:1, What If It Snaps Back To 15:1? | Glenn Jessome – Silver Tiger

Recommended

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Altamira Gold Encounters Porphyritic Intrusive Rocks In Initial Scout Drilling At Regional Targets

Related News

Psychedelics & The Need For Digital Therapeutic Solutions In Treating Mental Health

In terms of investment dollar inflows, one of the largest focuses of 2020 has arguably...

Sunday, November 1, 2020, 09:00:00 AM

Compass Pathways Granted Its Tenth Overall Patent Related To Psilocybin

Compass Pathways (NASDAQ: CMPS) this morning issued a brief release, indicating it has been granted...

Tuesday, November 23, 2021, 07:55:20 AM

Compass Pathways To Start Phase II Trial For Psilocybin PTSD Therapy

Compass Pathways (Nasdaq: CMPS) this morning announced that it will be launching the phase II...

Wednesday, November 3, 2021, 09:52:00 AM

Compass Pathways, Psilocybin Research Firm, Files For Nasdaq IPO

It appears that some authenticity and validation might be coming to the psychedelics space. Compass...

Saturday, August 29, 2020, 11:43:00 AM

David Nutt: Amanita Muscaria Due For More Research – The Daily Dive

Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt,...

Wednesday, March 10, 2021, 01:30:00 PM